Market capitalization | $254.90m |
Enterprise Value | $-127.07m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.81 |
EV/Sales (TTM) EV/Sales | -2,117.83 |
P/S ratio (TTM) P/S ratio | 4,248.33 |
P/B ratio (TTM) P/B ratio | 0.44 |
Revenue growth (TTM) Revenue growth | -99.87% |
Revenue (TTM) Revenue | $60.00k |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Lyell Immunopharma Inc forecast:
3 Analysts have issued a Lyell Immunopharma Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 0.06 0.06 |
100%
100%
|
|
Gross Profit | -20 -20 |
167%
167%
|
|
EBITDA | -201 -201 |
7%
7%
|
EBIT (Operating Income) EBIT | -221 -221 |
7%
7%
|
Net Profit | -204 -204 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Lynn Seely |
Employees | 224 |
Founded | 2018 |
Website | www.lyell.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.